Peter G. Rose
Expertise in
9
conditions

Dr. Peter G. Rose

Surgical Oncology
18200 Lorain Avenue, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
9
conditions
18200 Lorain Avenue, 
Cleveland, OH 

Overview

Peter Rose is a Surgical Oncologist practicing medicine in Cleveland, Ohio.

Dr. Rose is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Pseudomyxoma Peritonei, Desmoplastic Small Round Cell Tumor, Adult Soft Tissue Sarcoma, Hernia Surgery, and Tissue Biopsy.

Dr. Rose is board certified in American Board Of Obstetrics And Gynecology, 1990. He is actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 35 clinical trials. Dr. Rose is currently accepting new patients.

Specialties

Surgical Oncology

Licenses

Obstetrics & Gynecology in OH

Board Certifications

American Board Of Obstetrics And Gynecology, 1990

Fellowships

Roswell Park Cancer Institute

Hospital Affiliations

Ashtabula County Medical Center
Euclid Hospital
Cleveland Clinic
Fairview Hospital
Hillcrest Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Moll Cancer Center at Fairview Hospital
18200 Lorain Avenue, Cleveland, OH 44111
Other Locations
Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

35 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Tremelimumab
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Terminated
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

138 Total Publications

Correction: CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.
Correction: CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.
Journal: The Journal of experimental medicine
Published: July 30, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Jordan M. Winter
Surgical Oncology | General Surgery
Expertise in
16
conditions
Dr. Jordan M. Winter
Surgical Oncology | General Surgery
Referral may be required

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (11.8 miles away)
216-844-5777
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jordan Winter is a Surgical Oncologist and a General Surgeon practicing medicine in Cleveland, Ohio. Dr. Winter is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Winter is currently accepting new patients.

Expertise in
10
conditions
Dr. Julie E. Lang
Surgical Oncology
Expertise in
10
conditions
Dr. Julie E. Lang
Surgical Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (11.0 miles away)
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Julie Lang is a Surgical Oncologist practicing medicine in Cleveland, Ohio. Dr. Lang is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Intraductal Papilloma, HER-2 Positive Breast Cancer, and Lymphadenectomy. Dr. Lang is board certified in American Board Of Surgery, 2006. Dr. Lang is currently accepting new patients.

Expertise in
10
conditions
Dr. Chad M. Michener
Surgical Oncology
Expertise in
10
conditions
Dr. Chad M. Michener
Surgical Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (11.3 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chad Michener is a Surgical Oncologist practicing medicine in Cleveland, Ohio. Dr. Michener is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Eccrine Porocarcinoma, Melanoma, Desmoplastic Small Round Cell Tumor, Endoscopy, and Hernia Surgery. Dr. Michener is board certified in American Board Of Obstetrics And Gynecology, 2008. Dr. Michener is currently accepting new patients.

Frequently Asked Questions about Dr. Peter G. Rose

How do I make an appointment with Dr. Peter G. Rose?

You can book an appointment with Dr. Peter G. Rose by calling their office at 216-476-7606. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter G. Rose a top-rated expert for Pseudomyxoma Peritonei?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter G. Rose is classified as an Distinguished expert for Pseudomyxoma Peritonei, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter G. Rose specialize in?

While Dr. Peter G. Rose is a Surgical Oncology, they have specific expertise in Pseudomyxoma Peritonei, Desmoplastic Small Round Cell Tumor, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Peter G. Rose participate in research or clinical trials?

Yes. Dr. Peter G. Rose has published 138 articles and abstracts on conditions like Pseudomyxoma Peritonei. You can view a list of Dr. Peter G. Rose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter G. Rose accept my insurance?

Dr. Peter G. Rose accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 216-476-7606 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rose's expertise for a condition
ConditionClose
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile